US 2003/0125266 A1Published application

C12 Modified erythromycin macrolides and ketolides having antibacterial activity

AssigneeChiron Corporation

InventorsDaniel Chu, Matthew Burger, Xiaodong Lin, Georgia Law Carroll, Jacob Plattner, Alice Rico

Life of this patent

Estimating the term…

Abstract

Antimicrobial macrolide compounds are provided having formulas II: 1 as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

Claims10

Dependent claims

A compound having the formula II:

223
or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein
A. V is —OCORx, carbonyl, or a cladinose moiety of the formula:
224
wherein Rx is H, alkyl, —O-alkyl, —N(H)-alkyl, or —N(alkyl)2;
B. either Y and Z taken together define a group X, wherein X is selected from the group consisting of
(1) ═O,
(2) ═N—OH,
(3) ═N—O—R1 where R1 is selected from the group consisting of
(a) C1-C12-alkyl,
(b) C1-C12-alkyl substituted with alkoxy,
(c) C1-C12-alkyl substituted with aryl,
(d) C1-C12-alkyl substituted with substituted aryl,
(e) C1-C12-alkyl substituted with heteroaryl,
(f) C1-C12-alkyl substituted with substituted heteroaryl,
(g) C3-C12-cycloalkyl, and
(h) —Si—(R2)(R3)(R4) wherein R2, R3, R4 are each independently selected from C1-C12-alkyl and aryl;
and
(4) ═N—O—C(R5)(R6)—O—R1 wherein R'is as previously defined and R5 and R6 are each independently selected from the group consisting of
(a) hydrogen,
(b) C1-C12-alkyl,
(c) C1-C12-alkyl substituted with aryl,
(d) C1-C12-alkyl substituted with substituted aryl,
(e) C1-C12-alkyl substituted with heteroaryl, and
(f) C1-C12-alkyl substituted with substituted heteroaryl;
or R5 and R6 taken together with the atoms to which they are attached form a C3-C12-cycloalkyl ring;
or
Y and Z are ═N— when taken together with T to form a moiety of the structure
225
one of Y and Z is hydrogen and the other is selected from a group consisting of
(1) hydroxy,
(2) protected hydroxy, and
(3) NR7R8 wherein R7 and R8 are independently selected from hydrogen and alkyl, subsituted alkyl, or R7 and R8 are taken with the nitrogen atom to which they are connected to form a 3- to 7-membered ring which, when the ring is a 5- to 7-membered ring, may optionally contain a hetero function selected from the group consisting of —O—, —NH, —N(C1-C6-alkyl)-, —N(aryl)-, —N(aryl-C1-C6-alkyl-)-, —N(substituted-aryl-C1-C6-alkyl-)-, —N(heteroaryl)-, —N(heteroaryl-C1-C6-alkyl-)-, —N(substituted-heteroaryl-C1-C6-alkyl-)-, and —S— or S(O)n— wherein n is 1 or 2;
C. T is selected from the group consisting of —O—Rg, —O—, —NH—, N(W-Rf)-, and —CH(W-Rf)-, wherein
(1) W is absent or is selected from the group consisting of —O—, NH—CO—, —N═CH—, —NH— and —CH2—;
and
(2) Rf is selected from the group consisting of
(a) hydrogen,
(b) alkyl, alkenyl or alkynyl,
(c) alkyl, alkenyl or alkynyl substituted with one or more substituents selected from the group consisting of
(i) aryl,
(ii) substituted aryl,
(iii) heteroaryl,
(iv) substituted heteroaryl,
(v) hydroxy,
(vi) C1-C6-alkoxy,
(vii) —NR7R8 wherein R7 and R8 are as defined previously, and
(viii) -M-R9, wherein M is selected from the group consisting of:
(a) —C(O)—NH—,
(b) —NH—C(O)—,
(c) —NH—,
(d) —N═,
(e) —N(CH3)—,
(f) —NH—C(O)—O—,
(g) —NH—C(O)—NH—,
(h) —O—C(O)—NH——,
(i) —O—C(O)—O—,
(j) —O—,
(k) —S(O)n—, wherein n is 0, 1 or 2,
(l) —C(O)—O—,
(m) —O—C(O)—,
(n) —C(O)—;
and
and R9 is selected from the group consisting of:
(a) alkyl optionally substituted with a substituent selected from the group consisting of
(aa) aryl,
(bb) substituted aryl,
(cc) heteroaryl, and
(dd) substituted heteroaryl,
(b) aryl,
(c) substituted aryl,
(d) heteroaryl,
(e) substituted heteroaryl, and
(f) heterocycloalkyl,
D. R is selected from the group consisting of
(1) hydrogen;
(2) methyl substituted with a moiety selected from the group consisting of
(a) CN,
(b) F,
(c) —CO2R10 wherein R10 is C1-C3-alkyl or aryl substituted C1-C3-alkyl, or heteroaryl substituted C1-C3-alkyl,
(d) —S(O)n R10—, wherein n is 0, 1 or 2 and R10 is as previously defined,
(e) —NH—C(O) R10, wherein R10 is as previously defined,
(f) —NH—C(O)N R11 R12 wherein R11 and R12 are independently selected from hydrogen, C1-C3-alkyl, C1-C3-alkyl substituted with aryl, substituted aryl, heteroaryl, substituted heteroaryl,
(g) aryl,
(h) substituted aryl,
(i) heteroaryl, and
(j) substituted heteroaryl;
(3) alkyl;
(4) C2-C12-alkyl substituted with one or more substituents selected from the group consisting of
(a) halogen,
(b) hydroxy,
(c) C1-C3-alkoxy,
(d) C1-C3-alkoxy-C1-C3-alkoxy,
(e) oxo,
(f) O-SO2-(substituted C1-C6-alkyl),
(g) —N3,
(h) —CHO,
(i) —NR13R14 wherein R13 and R14 are selected from the group consisting of
(i) hydrogen,
(ii) C1-C12-alkyl,
(iii) substituted C1-C12-alkyl,
(iv) C2-C12-alkenyl,
(v) substituted C2-C12-alkenyl,
(vi) C2-C12-alkynyl,
(vii) substituted C2-C12-alkynyl,
(viii) aryl,
(ix) C3-C8-cycloalkyl,
(x) substituted C3-C8-cycloalkyl,
(xi) substituted aryl,
(xii) heterocycloalkyl,
(xiii) substituted heterocycloalkyl,
(xiv) C1-C12-alkyl substituted with aryl,
(xv) C1-C12-alkyl substituted with substituted aryl,
(xvi) C1-C12-alkyl substituted with heterocycloaryl,
(xvii) C1-C12-alkyl substituted with substituted heterocycloaryl,
(xviii) C1-C12-alkyl substituted with C3-C8-cycloalkyl,
(xix) C1-C12-alkyl substituted with substituted C3-C8-cycloalkyl,
(xx) heteroaryl,
(xxi) substituted heteroaryl,
(xxii) C1-C12-alkyl substituted with heteroaryl, and
(xxiii) C1-C12-alkyl substituted with substituted heteroaryl;
or R13 and R14 are taken together with the atom to which they are attached form a 3- to 10-membered heterocycloalkyl ring which may optionally be substituted with one or more substituents independently selected from the group consisting of
(i) halogen,
(ii) hydroxy,
(iii) C1-C3-alkoxy,
(iv) C1-C3-alkoxy-C1-C3-alkoxy,
(v) oxo,
(vi) C1-C3-alkyl,
(vii) halo-C1-C3-alkyl, and
(viii) C1-C3-alkoxy-C1-C3-alkyl;
(j) —CO2R10 wherein R10 is as previously defined,
(k) —C(O)R11R12 wherein R11 and R12 are as previously defined,
(l) ═N—O—R10 wherein R10 is as previously defined,
(m) —CN,
(n) —O—S(O)nR10 wherein n is 0, 1 or 2 and R10 is as previously defined,
(o) aryl,
(p) substituted aryl,
(q) heteroaryl,
(r) substituted heteroaryl,
(s) C3-C8-cycloalkyl,
(t) substituted C3-C8-cycloalkyl,
(u) C1-C12-alkyl substituted with heteroaryl,
(v) heterocycloalkyl,
(w) substituted heterocycloalkyl,
(x) —NH—C(O)R10 wherein R10 is as previously defined,
(y) —NH—C(O)NR11R12 wherein R11 and R12 are as previously defined,
(z) ═N—NR13R14 wherein R13 and R14 are as previously defined,
(aa) ═N—R9 wherein R9 is as previously defined,
(bb) ═N—NH—C(O)R10 wherein R10 is as previously defined, and
(cc) ═N—NH—C(O)NR11 R12 wherein R11 and R12 are as previously defined;
(5) C3-alkenyl substituted with a moiety selected from the group consisting of
(a) halogen,
(b) —CHO,
(c) —CO2R10 wherein R10 is as previously defined,
(d) —C(O)NR11R12 wherein R11 and R12 are as previously defined,
(e) —C(O)R9 wherein R9 is as previously defined,
(f) —CN,
(g) aryl,
(h) substituted aryl,
(i) heteroaryl,
(j) substituted heteroaryl,
(k) C3-C8-cycloalkyl, and
(l) C1-C12-alkyl substituted with heteroaryl;
(6) C4-C10-alkenyl;
(7) C4-C10-alkenyl substituted with one or more substituents selected from the group consisting of
(a) halogen,
(b) C1-C3-alkoxy,
(c) oxo,
(d) —CHO,
(e) —CO2R10 wherein R10 is as previously defined,
(f) —C(O)NR11R12 wherein R11 and R12 are as previously defined,
(g) NR13R14 wherein R13 and R14 are as previously defined,
(h) ═N—O—R10 wherein R10 is as previously defined,
(i) —CN,
(j) —O—S(O)n R10 wherein n is 0, 1 or 2 and R10 is as previously defined,
(k) aryl,
(l) substituted aryl,
(m) heteroaryl,
(n) substituted heteroaryl,
(o) C3-C8-cycloalkyl,
(p) C1-C12-alkyl substituted with substituted heteroaryl,
(q) —NH—C(O)R10 wherein R10 is as previously defined,
(r) —NH—C(O)NR11R12 wherein R11 and R12 are as previously defined,
(s) ═N—NR13R14 wherein R13 and R14 are as previously defined,
(t) ═N—R9 wherein R9 is as previously defined,
(u) ═N—NH—C(O)R10 wherein R10 is as previously defined, and
(v) ═N—NH—C(O)NR11R12 wherein R11 and R12 are as previously defined;
(8) C3-C10-alkynyl;
(9) C3-C10-alkynyl substituted with one or more substituents selected from the group consisting of
(a) trialkylsilyl,
(b) aryl,
(c) substituted aryl,
(d) heteroaryl, and
(e) substituted heteroaryl;
and
(10) C(O)NR7R8 where R7 and R8 are previously defined;
E. Ra is selected from a group consisting of
(1) hydrogen;
(2) C1 alkyl further substituted with a one or more substituents selected from a group consisting of
(a) hydroxyl,
(b) halogen,
(c) thiol, which can be further subsituted with and alkyl or subsituted alkyl group
(d) C1-C12-alkyl which can be further substituted by halogen, hydroxyl alkoxy, or amino,
(e) C1-C3-alkoxy,
(f) C1-C3-thioalkoxy,
(g) amino,
(h) alkylamino,
(i) dialkylamino,
(j) nitrile,
(k) nitro,
(l) amido,
(m) carboxylic acid,
(n) ester,
(o) azido,
(p) ═N—O—R10, wherein R10 is as previously defined,
(q) ═N—R9, wherein R9 is as previously defined,
(r) ═N—NR13R14, wherein R13 and R14 are as previously defined,
(s) ═N—NH—C(O)R10, wherein R10 is as previously defined, and
(t) ═N—NH—C(O)NR11R12, wherein R11 and R12 are as previously defined;
(3) C2-C4-alkenyl, which can be further substituted with C1-C12-alkyl and one or more halo groups;
(4) —C2-C4-alkynyl, which can be further substituted with C1-C12-alkyl and one or more halo groups;
(5) aryl, which can be further substituted with C1-C12-alkyl and one or more halo groups;
(6) CHO;
(7) —CO2H;
(8) —CN;
(9) —CO2R10, wherein R10 is as previously defined;
(10) —C(O)NR11R12, wherein R11 and R12 are as previously defined;
(11) —C(O)R9 wherein R9 is as previously defined;
and
(12) thioester;
with the proviso that in formula II, when Z is amino or substituted amino, then Ra can not be —CH2OH, —NR4R6, or —(CH2)n NR4R6, wherein R4 and R6 are selected from the group consisting of hydrogen, loweralkyl and aralkyl;
F. Rb is hydrogen, halogen or C1-C12-alkyl which can be further substituted by one or more halo groups, or Rb can be taken together with V to form a double bond;
G. Rc is hydrogen or a hydroxy protecting group;
H. Rd is selected from the group consisting of
(1) C1-C12-alkyl,
(2) C1-C12-alkyl substituted with one or more substituents selected from the group consisting of
(a) halogen,
(b) hydroxy, and
(c) C1-C3-alkoxy,
(3) C3-C7-cycloalkyl,
(4) C2-C4-alkenyl, and
(5) C2-C4-alkynyl;
I. Re is hydroxyl, amino, or alkylamino;
or Re and Ra may be taken together to form an epoxide, a carbonyl, an olefin, or a subsituted olefin;
or Re and Ra when taken together with the atom to which they are attached form a spiro ring consisting of C3-C7-carbocyclic, carbonate or carbamate wherein the nitrogen atom can be unsubstituted or substituted with an alkyl group;
or Re and T when taken together with the carbon atoms to which they are attached form a ring of the structure
226
wherein L is methylene or carbonyl and P is —O—, —NH— or —NR1— wherein R1 is as previously defined;
provided that when L is methylene, T is —O— and P is —O—;
J. Rg is hydrogen, R where R is as previously defined;
or Rg may be taken together with Y, seperated by a linker of the formula —C(═O)— or —C(CH3)2—, to form a cyclic moiety;
K. Rh is selected from the group consisting of
(1) hydrogen,
(2) —ORj, where Rj is hydrogen or a hydroxy protecting group,
(3) halogen,
(4) OC(O)NHRi wherein Ri is selected from a group consisting of
(a) C1-C4 alkyl,
(b) C1-C4 aminoalkyl where the amino group is substituted with one or two groups selected from
(i) C1-C4 alkyl,
(ii) C1-C4 alkyl substituted with halogen,
(iii) C1-C4 alkyl substituted with alkoxy,
(iv) C1-C4 alkyl substituted with hydroxyl,
(v) C1-C4 alkyl substituted with aryl,
(vi) C1-C4 alkyl substituted with substituted aryl,
(vii) C1-C4 alkyl substituted with heteroaryl,
(viii) C1-C4 alkyl substituted with substituted heteroaryl,
(ix) C3-C6 cycloalkyl;
and
L. A, B, D, and E are independently selected from the group consisting of:
(1) hydrogen;
(2) C1-C6-alkyl optionally substituted with one or more substituents selected from the group consisting of:
(a) aryl,
(b) substituted aryl,
(c) heteroaryl,
(d) substituted heteroaryl,
(e) heterocycloalkyl,
(f) hydroxy,
(g) C1-C6-alkoxy,
(h) halogen selected from the group consisting of Br, Cl, F or I, and
(i) NR7R8 where R7 and R8 are as previously defined;
(3) C3-C7-cycloalkyl;
(4) aryl;
(5) substituted aryl;
(6) heteroaryl;
(7) substituted heteroaryl;
(8) heterocycloalkyl;
and
(9) a group selected from option (2) above further substituted with -M-R9,
wherein M and R9 are as previously defined;
or
any one pair of substituents, consisting of AB, AD, AE, BD, BE or DE, is taken together with the atom or atoms to which they are attached to form a 3- to 7-membered ring optionally containing a hetero function selected from the group consisting of —O—, —NH—, —N(C1-C6-alkyl-)-, —N(aryl-C1-C6-alkyl-)-, —N(substituted-aryl-C1-C6-alkyl-)-, —N(heteroaryl-C1-C6-alkyl-)-, —N(substituted-heteroaryl-C1-C6-alkyl-)-, —S— or —S(O)n—, wherein n is 1 or 2,—C(O)—NH, —C(O)—NR12, wherein R12 is as previously defined, —NH—C(O)—, —NR12—C(O)—, wherein R12 is as previously defined, and —C(50 NH)—NH—;
with the provision that at least two of A, B, D, and E are hydrogen;
or a pharmaceutically acceptable salt, ester or prodrug thereof.

290 more elements

Dependencies are inferred from the claim text.

Facts

Application: 10/190,431Filed 3 Jul 2002
Priority: 3 Jul 2001
Published: 3 Jul 2003
Term ends: Not estimatedThe source records don’t support an estimate.

Classification5 codes

C07H 17/08
Heterocyclic radicals containing only oxygen as ring hetero atoms: hetero rings containing eight or more ring members, e.g. erythromycins
A61P 31/04
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antibacterial agents
A61P 43/00
Drugs for specific purposes, not provided for in groups a61p1/00-a61p41/00
C07H
Sugars

Family

Application60/302,825Us provisional application · filed 3 Jul 2001
US 6,756,359 B2Related patent
US 2003/0125266 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

A compound having the formula II:

223
or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein
A. V is —OCORx, carbonyl, or a cladinose moiety of the formula:
224
wherein Rx is H, alkyl, —O-alkyl, —N(H)-alkyl, or —N(alkyl)2;
B. either Y and Z taken together define a group X, wherein X is selected from the group consisting of
(1) ═O,
(2) ═N—OH,
(3) ═N—O—R1 where R1 is selected from the group consisting of
(a) C1-C12-alkyl,
(b) C1-C12-alkyl substituted with alkoxy,
(c) C1-C12-alkyl substituted with aryl,
(d) C1-C12-alkyl substituted with substituted aryl,
(e) C1-C12-alkyl substituted with heteroaryl,
(f) C1-C12-alkyl substituted with substituted heteroaryl,
(g) C3-C12-cycloalkyl, and
(h) —Si—(R2)(R3)(R4) wherein R2, R3, R4 are each independently selected from C1-C12-alkyl and aryl;
and
(4) ═N—O—C(R5)(R6)—O—R1 wherein R'is as previously defined and R5 and R6 are each independently selected from the group consisting of
(a) hydrogen,
(b) C1-C12-alkyl,
(c) C1-C12-alkyl substituted with aryl,
(d) C1-C12-alkyl substituted with substituted aryl,
(e) C1-C12-alkyl substituted with heteroaryl, and
(f) C1-C12-alkyl substituted with substituted heteroaryl;
or R5 and R6 taken together with the atoms to which they are attached form a C3-C12-cycloalkyl ring;
or
Y and Z are ═N— when taken together with T to form a moiety of the structure
225
one of Y and Z is hydrogen and the other is selected from a group consisting of
(1) hydroxy,
(2) protected hydroxy, and
(3) NR7R8 wherein R7 and R8 are independently selected from hydrogen and alkyl, subsituted alkyl, or R7 and R8 are taken with the nitrogen atom to which they are connected to form a 3- to 7-membered ring which, when the ring is a 5- to 7-membered ring, may optionally contain a hetero function selected from the group consisting of —O—, —NH, —N(C1-C6-alkyl)-, —N(aryl)-, —N(aryl-C1-C6-alkyl-)-, —N(substituted-aryl-C1-C6-alkyl-)-, —N(heteroaryl)-, —N(heteroaryl-C1-C6-alkyl-)-, —N(substituted-heteroaryl-C1-C6-alkyl-)-, and —S— or S(O)n— wherein n is 1 or 2;
C. T is selected from the group consisting of —O—Rg, —O—, —NH—, N(W-Rf)-, and —CH(W-Rf)-, wherein
(1) W is absent or is selected from the group consisting of —O—, NH—CO—, —N═CH—, —NH— and —CH2—;
and
(2) Rf is selected from the group consisting of
(a) hydrogen,
(b) alkyl, alkenyl or alkynyl,
(c) alkyl, alkenyl or alkynyl substituted with one or more substituents selected from the group consisting of
(i) aryl,
(ii) substituted aryl,
(iii) heteroaryl,
(iv) substituted heteroaryl,
(v) hydroxy,
(vi) C1-C6-alkoxy,
(vii) —NR7R8 wherein R7 and R8 are as defined previously, and
(viii) -M-R9, wherein M is selected from the group consisting of:
(a) —C(O)—NH—,
(b) —NH—C(O)—,
(c) —NH—,
(d) —N═,
(e) —N(CH3)—,
(f) —NH—C(O)—O—,
(g) —NH—C(O)—NH—,
(h) —O—C(O)—NH——,
(i) —O—C(O)—O—,
(j) —O—,
(k) —S(O)n—, wherein n is 0, 1 or 2,
(l) —C(O)—O—,
(m) —O—C(O)—,
(n) —C(O)—;
and
and R9 is selected from the group consisting of:
(a) alkyl optionally substituted with a substituent selected from the group consisting of
(aa) aryl,
(bb) substituted aryl,
(cc) heteroaryl, and
(dd) substituted heteroaryl,
(b) aryl,
(c) substituted aryl,
(d) heteroaryl,
(e) substituted heteroaryl, and
(f) heterocycloalkyl,
D. R is selected from the group consisting of
(1) hydrogen;
(2) methyl substituted with a moiety selected from the group consisting of
(a) CN,
(b) F,
(c) —CO2R10 wherein R10 is C1-C3-alkyl or aryl substituted C1-C3-alkyl, or heteroaryl substituted C1-C3-alkyl,
(d) —S(O)n R10—, wherein n is 0, 1 or 2 and R10 is as previously defined,
(e) —NH—C(O) R10, wherein R10 is as previously defined,
(f) —NH—C(O)N R11 R12 wherein R11 and R12 are independently selected from hydrogen, C1-C3-alkyl, C1-C3-alkyl substituted with aryl, substituted aryl, heteroaryl, substituted heteroaryl,
(g) aryl,
(h) substituted aryl,
(i) heteroaryl, and
(j) substituted heteroaryl;
(3) alkyl;
(4) C2-C12-alkyl substituted with one or more substituents selected from the group consisting of
(a) halogen,
(b) hydroxy,
(c) C1-C3-alkoxy,
(d) C1-C3-alkoxy-C1-C3-alkoxy,
(e) oxo,
(f) O-SO2-(substituted C1-C6-alkyl),
(g) —N3,
(h) —CHO,
(i) —NR13R14 wherein R13 and R14 are selected from the group consisting of
(i) hydrogen,
(ii) C1-C12-alkyl,
(iii) substituted C1-C12-alkyl,
(iv) C2-C12-alkenyl,
(v) substituted C2-C12-alkenyl,
(vi) C2-C12-alkynyl,
(vii) substituted C2-C12-alkynyl,
(viii) aryl,
(ix) C3-C8-cycloalkyl,
(x) substituted C3-C8-cycloalkyl,
(xi) substituted aryl,
(xii) heterocycloalkyl,
(xiii) substituted heterocycloalkyl,
(xiv) C1-C12-alkyl substituted with aryl,
(xv) C1-C12-alkyl substituted with substituted aryl,
(xvi) C1-C12-alkyl substituted with heterocycloaryl,
(xvii) C1-C12-alkyl substituted with substituted heterocycloaryl,
(xviii) C1-C12-alkyl substituted with C3-C8-cycloalkyl,
(xix) C1-C12-alkyl substituted with substituted C3-C8-cycloalkyl,
(xx) heteroaryl,
(xxi) substituted heteroaryl,
(xxii) C1-C12-alkyl substituted with heteroaryl, and
(xxiii) C1-C12-alkyl substituted with substituted heteroaryl;
or R13 and R14 are taken together with the atom to which they are attached form a 3- to 10-membered heterocycloalkyl ring which may optionally be substituted with one or more substituents independently selected from the group consisting of
(i) halogen,
(ii) hydroxy,
(iii) C1-C3-alkoxy,
(iv) C1-C3-alkoxy-C1-C3-alkoxy,
(v) oxo,
(vi) C1-C3-alkyl,
(vii) halo-C1-C3-alkyl, and
(viii) C1-C3-alkoxy-C1-C3-alkyl;
(j) —CO2R10 wherein R10 is as previously defined,
(k) —C(O)R11R12 wherein R11 and R12 are as previously defined,
(l) ═N—O—R10 wherein R10 is as previously defined,
(m) —CN,
(n) —O—S(O)nR10 wherein n is 0, 1 or 2 and R10 is as previously defined,
(o) aryl,
(p) substituted aryl,
(q) heteroaryl,
(r) substituted heteroaryl,
(s) C3-C8-cycloalkyl,
(t) substituted C3-C8-cycloalkyl,
(u) C1-C12-alkyl substituted with heteroaryl,
(v) heterocycloalkyl,
(w) substituted heterocycloalkyl,
(x) —NH—C(O)R10 wherein R10 is as previously defined,
(y) —NH—C(O)NR11R12 wherein R11 and R12 are as previously defined,
(z) ═N—NR13R14 wherein R13 and R14 are as previously defined,
(aa) ═N—R9 wherein R9 is as previously defined,
(bb) ═N—NH—C(O)R10 wherein R10 is as previously defined, and
(cc) ═N—NH—C(O)NR11 R12 wherein R11 and R12 are as previously defined;
(5) C3-alkenyl substituted with a moiety selected from the group consisting of
(a) halogen,
(b) —CHO,
(c) —CO2R10 wherein R10 is as previously defined,
(d) —C(O)NR11R12 wherein R11 and R12 are as previously defined,
(e) —C(O)R9 wherein R9 is as previously defined,
(f) —CN,
(g) aryl,
(h) substituted aryl,
(i) heteroaryl,
(j) substituted heteroaryl,
(k) C3-C8-cycloalkyl, and
(l) C1-C12-alkyl substituted with heteroaryl;
(6) C4-C10-alkenyl;
(7) C4-C10-alkenyl substituted with one or more substituents selected from the group consisting of
(a) halogen,
(b) C1-C3-alkoxy,
(c) oxo,
(d) —CHO,
(e) —CO2R10 wherein R10 is as previously defined,
(f) —C(O)NR11R12 wherein R11 and R12 are as previously defined,
(g) NR13R14 wherein R13 and R14 are as previously defined,
(h) ═N—O—R10 wherein R10 is as previously defined,
(i) —CN,
(j) —O—S(O)n R10 wherein n is 0, 1 or 2 and R10 is as previously defined,
(k) aryl,
(l) substituted aryl,
(m) heteroaryl,
(n) substituted heteroaryl,
(o) C3-C8-cycloalkyl,
(p) C1-C12-alkyl substituted with substituted heteroaryl,
(q) —NH—C(O)R10 wherein R10 is as previously defined,
(r) —NH—C(O)NR11R12 wherein R11 and R12 are as previously defined,
(s) ═N—NR13R14 wherein R13 and R14 are as previously defined,
(t) ═N—R9 wherein R9 is as previously defined,
(u) ═N—NH—C(O)R10 wherein R10 is as previously defined, and
(v) ═N—NH—C(O)NR11R12 wherein R11 and R12 are as previously defined;
(8) C3-C10-alkynyl;
(9) C3-C10-alkynyl substituted with one or more substituents selected from the group consisting of
(a) trialkylsilyl,
(b) aryl,
(c) substituted aryl,
(d) heteroaryl, and
(e) substituted heteroaryl;
and
(10) C(O)NR7R8 where R7 and R8 are previously defined;
E. Ra is selected from a group consisting of
(1) hydrogen;
(2) C1 alkyl further substituted with a one or more substituents selected from a group consisting of
(a) hydroxyl,
(b) halogen,
(c) thiol, which can be further subsituted with and alkyl or subsituted alkyl group
(d) C1-C12-alkyl which can be further substituted by halogen, hydroxyl alkoxy, or amino,
(e) C1-C3-alkoxy,
(f) C1-C3-thioalkoxy,
(g) amino,
(h) alkylamino,
(i) dialkylamino,
(j) nitrile,
(k) nitro,
(l) amido,
(m) carboxylic acid,
(n) ester,
(o) azido,
(p) ═N—O—R10, wherein R10 is as previously defined,
(q) ═N—R9, wherein R9 is as previously defined,
(r) ═N—NR13R14, wherein R13 and R14 are as previously defined,
(s) ═N—NH—C(O)R10, wherein R10 is as previously defined, and
(t) ═N—NH—C(O)NR11R12, wherein R11 and R12 are as previously defined;
(3) C2-C4-alkenyl, which can be further substituted with C1-C12-alkyl and one or more halo groups;
(4) —C2-C4-alkynyl, which can be further substituted with C1-C12-alkyl and one or more halo groups;
(5) aryl, which can be further substituted with C1-C12-alkyl and one or more halo groups;
(6) CHO;
(7) —CO2H;
(8) —CN;
(9) —CO2R10, wherein R10 is as previously defined;
(10) —C(O)NR11R12, wherein R11 and R12 are as previously defined;
(11) —C(O)R9 wherein R9 is as previously defined;
and
(12) thioester;
with the proviso that in formula II, when Z is amino or substituted amino, then Ra can not be —CH2OH, —NR4R6, or —(CH2)n NR4R6, wherein R4 and R6 are selected from the group consisting of hydrogen, loweralkyl and aralkyl;
F. Rb is hydrogen, halogen or C1-C12-alkyl which can be further substituted by one or more halo groups, or Rb can be taken together with V to form a double bond;
G. Rc is hydrogen or a hydroxy protecting group;
H. Rd is selected from the group consisting of
(1) C1-C12-alkyl,
(2) C1-C12-alkyl substituted with one or more substituents selected from the group consisting of
(a) halogen,
(b) hydroxy, and
(c) C1-C3-alkoxy,
(3) C3-C7-cycloalkyl,
(4) C2-C4-alkenyl, and
(5) C2-C4-alkynyl;
I. Re is hydroxyl, amino, or alkylamino;
or Re and Ra may be taken together to form an epoxide, a carbonyl, an olefin, or a subsituted olefin;
or Re and Ra when taken together with the atom to which they are attached form a spiro ring consisting of C3-C7-carbocyclic, carbonate or carbamate wherein the nitrogen atom can be unsubstituted or substituted with an alkyl group;
or Re and T when taken together with the carbon atoms to which they are attached form a ring of the structure
226
wherein L is methylene or carbonyl and P is —O—, —NH— or —NR1— wherein R1 is as previously defined;
provided that when L is methylene, T is —O— and P is —O—;
J. Rg is hydrogen, R where R is as previously defined;
or Rg may be taken together with Y, seperated by a linker of the formula —C(═O)— or —C(CH3)2—, to form a cyclic moiety;
K. Rh is selected from the group consisting of
(1) hydrogen,
(2) —ORj, where Rj is hydrogen or a hydroxy protecting group,
(3) halogen,
(4) OC(O)NHRi wherein Ri is selected from a group consisting of
(a) C1-C4 alkyl,
(b) C1-C4 aminoalkyl where the amino group is substituted with one or two groups selected from
(i) C1-C4 alkyl,
(ii) C1-C4 alkyl substituted with halogen,
(iii) C1-C4 alkyl substituted with alkoxy,
(iv) C1-C4 alkyl substituted with hydroxyl,
(v) C1-C4 alkyl substituted with aryl,
(vi) C1-C4 alkyl substituted with substituted aryl,
(vii) C1-C4 alkyl substituted with heteroaryl,
(viii) C1-C4 alkyl substituted with substituted heteroaryl,
(ix) C3-C6 cycloalkyl;
and
L. A, B, D, and E are independently selected from the group consisting of:
(1) hydrogen;
(2) C1-C6-alkyl optionally substituted with one or more substituents selected from the group consisting of:
(a) aryl,
(b) substituted aryl,
(c) heteroaryl,
(d) substituted heteroaryl,
(e) heterocycloalkyl,
(f) hydroxy,
(g) C1-C6-alkoxy,
(h) halogen selected from the group consisting of Br, Cl, F or I, and
(i) NR7R8 where R7 and R8 are as previously defined;
(3) C3-C7-cycloalkyl;
(4) aryl;
(5) substituted aryl;
(6) heteroaryl;
(7) substituted heteroaryl;
(8) heterocycloalkyl;
and
(9) a group selected from option (2) above further substituted with -M-R9,
wherein M and R9 are as previously defined;
or
any one pair of substituents, consisting of AB, AD, AE, BD, BE or DE, is taken together with the atom or atoms to which they are attached to form a 3- to 7-membered ring optionally containing a hetero function selected from the group consisting of —O—, —NH—, —N(C1-C6-alkyl-)-, —N(aryl-C1-C6-alkyl-)-, —N(substituted-aryl-C1-C6-alkyl-)-, —N(heteroaryl-C1-C6-alkyl-)-, —N(substituted-heteroaryl-C1-C6-alkyl-)-, —S— or —S(O)n—, wherein n is 1 or 2,—C(O)—NH, —C(O)—NR12, wherein R12 is as previously defined, —NH—C(O)—, —NR12—C(O)—, wherein R12 is as previously defined, and —C(50 NH)—NH—;
with the provision that at least two of A, B, D, and E are hydrogen;
or a pharmaceutically acceptable salt, ester or prodrug thereof.

290 more elements

Facts

Application

10/190,431Filed 3 Jul 2002

Priority

3 Jul 2001

Published

3 Jul 2003

Term ends

Not estimatedThe source records don’t support an estimate.

Classification5 codes

C07H 17/08
Heterocyclic radicals containing only oxygen as ring hetero atoms: hetero rings containing eight or more ring members, e.g. erythromycins
A61P 31/04
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antibacterial agents
A61P 43/00
Drugs for specific purposes, not provided for in groups a61p1/00-a61p41/00
C07H
Sugars